Roy C. Levitt, M.D., Genaera's CEO, resigned effective December 31, 2005, and John (Jack) L. Armstrong, Jr., the company's president and COO, will succeed him as Genaera's interim CEO. It is expected that Dr. Levitt will complete his term on the company's board of directors and continue as a consultant to the company.
VWR International has named John M. Ballbach CEO. He replaces James W. Rogers, a CD&R operating partner, who will continue to serve as chairman.
Neurotech has appointed Ted Danse as its new president and CEO. Previously he served as president and CEO of ISTA Pharmaceuticals.
Mark D. Perrin has been named president and CEO of ConjuChem. Outgoing president and interim CEO Jacques Lapointe will remain as executive chairman. Perrin had been executive vice president and chief commercial officer at Orphan Medical.
Medmark has named Stanley B. Blaylock as CEO. He has been president since June 2005.
AXM Pharma has appointed Madam Wang Weishi as its CEO, effective immediately, replacing Chet Howard, the former CEO/CFO of the company, who resigned. Madam Wang, the founder of AXM Shenyang and its general manager since its inception in 1998, has served as chairperson of the company's board since the company's inception.
Alliance Pharmaceutical has named Jack DeFranco president and COO. DeFranco was vice president of business development and marketing with Alliance for 10 years prior to serving as senior vice president and COO of IMCOR Pharmaceutical.
PPD has appointed Agostino Fede, Ph.D., as senior vice president of global central labs. Fede had previously served as vice president of operations and sales director for Covance Central Laboratories in Europe. William W. Richardson was named senior vice president of global business development. Frank Casieri, who is stepping down from that role as planned, will continue his service with PPD as a part-time employee for an interim transition period.
Antigenics announced that Jill M. Forrest has been appointed to the newly created position of vice president of marketing and sales. She was most recently director of global marketing at Bristol-Myers Squibb Oncology.
Liponex has appointed Kenneth Sokoll to the position of vice president of drug development Sokoll spent four years at United Biomedical, where he began as management of the formulations group and then moved on to management of the formulation and API/adjuvant development group, ultimately holding the position of vice president of vaccine product development, where he was responsible as head of regulatory affairs.
Sigma-Aldrich has named Doug Rau vice president of human resources.
BioAdvance has named Ezra Felker as the organization's most recent "entrepreneur-in-residence." Prior to joining BioAdvance, Mr. Felker was associate vice president, BTGVentures where he co-managed BTG's global healthcare portfolio with primary responsibility for North America.
Verus Pharmaceuticals has appointed Adam K. Simpson as general counsel. Through his prior position at Latham & Watkins, Simpson has provided legal support for Verus since 2003.
Charles A. Sanders, M.D., who has served on the Icagen board of directors since 1997, has been appointed chairman of Icagen's board.
Greg Peet, a former CEO and chairman of A.L.I. Technologies, has been appointed to Angiotech's board of directors.
The board of Eli Lilly has elected J. Erik Fyrwald, group vice-president of DuPont Agriculture and Nutrition, as a new member.
Intranasal Therapeutics has named two new members to its board of directors: Lisa Giles, president and founder of Giles & Associates Consultancy, and Paul Ashton, Ph.D., president and CEO of Control Delivery Systems.
Argolyn Bioscience announced that W. Thomas Amick has been elected to its board of directors.
Novelos Therapeutics has elected Michael J. Doyle to serve on its board of directors.